NCT03661307: Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 129 taking part
- Started
- 31 Oct 2018
- Primary completion
- 1 Jan 2028
- Arms
- Treatment (decitabine, quizartinib, venetoclax)
- Results
- None posted
- 7 Sep 2018: Trial registered
- 31 Oct 2018: Trial started